Brief Summary

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTAalone on you and your malignant pleural mesothelioma as well as make ALIMTA available topatients who qualify for treatment.

Status
Approved for marketing
Conditions
Mesothelioma
Interventions

Drug: Pemetrexed

Drug: Cisplatin

Eligibility Criteria

Inclusion Criteria:

- Have a proven diagnosis of malignant mesothelioma in patients not candidates for
curative surgery

- Prior chemotherapy for your disease is allowed

- Measurable lesion is not required

- Have a adequate performance status

- Sign an informed consent form

Exclusion Criteria:

- You are excluded from this trial if you have received any investigational agent
within 4 week before enrolling in this study

- You are excluded from this trial if you have received radiation within the previous
2 weeks

- You are excluded from this trial if you are a candidates for curative surgery

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Brazil
Egypt
Saudi Arabia
United States
Locations

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Basking Ridge, New Jersey, United States

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Porto Alegre, RS, Brazil

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Sao Paulo, Brazil

"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician."
Cairo, Egypt

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Cairo, Egypt

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Jeddah, Saudi Arabia

Sponsors / Collaborators
Eli Lilly and Company
NCT Number
NCT00040625
MeSH Terms
Mesothelioma
Mesothelioma, Malignant
Pemetrexed